Novel farnesylthiosalicylate (FTS)-eluting composite structures

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Polymer Chemistry

Background:

• Farnesylthiosalicylate (FTS) is a novel, non-toxic Ras antagonist with potential applications in cancer treatment and medical devices.
• Developing effective drug delivery systems is crucial for optimizing therapeutic efficacy and minimizing side effects.

Purpose of the Study:

• To investigate the drug release mechanism of FTS from bioresorbable core/shell fiber structures.
• To explore the influence of formulation and process kinetics on FTS release profiles.
• To establish a controlled release system for the new drug FTS.

Main Methods:

• Fabrication of FTS-loaded core/shell fibers using polyglyconate and poly(d,l-lactic-glycolic acid) via freeze-drying of inverted emulsions.
• Analysis of FTS release kinetics over 15-40 days.
• Evaluation of shell morphology and polymer degradation effects on drug release.
• Investigating the impact of emulsion composition and process parameters on release behavior.

Main Results:

• FTS release exhibited an initial burst effect followed by a sustained release over 15-40 days.
• Drug release was influenced by water uptake, polymer swelling, and degradation.
• Emulsion stability and microstructure significantly impacted the release profile.
• Copolymer composition was identified as the most critical factor governing FTS release.

Conclusions:

• Bioresorbable core/shell fibers provide a viable platform for controlled FTS delivery.
• Understanding the interplay between formulation, process, and microstructure is key to optimizing drug release.
• This work represents the first report on the controlled release of FTS using such a system.